Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double Blind, Placebo-Controlled Study to Explore the Safety, Tolerability, and Activity of SXC-2023 in Adults With Moderate to Severe Trichotillomania (TTM) When Dosed for 6 Weeks

Next Previous
Search
Trial Profile

A Phase 2, Double Blind, Placebo-Controlled Study to Explore the Safety, Tolerability, and Activity of SXC-2023 in Adults With Moderate to Severe Trichotillomania (TTM) When Dosed for 6 Weeks

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SXC-2023 (Primary)
  • Indications Trichotillomania
  • Focus Adverse reactions
  • Sponsors Promentis Pharmaceuticals

    • Most Recent Events

    • 31 Oct 2020 According to a Promentis Pharmaceuticals media release, data from this study will be presented by Dr. Chad E. Beyer at the 11th Anniversary CNS Summit.
    • 04 Mar 2020 Status changed from active, no longer recruiting to completed.
    • 31 Oct 2019 According to a Promentis Pharmaceuticals media release, this study onducted in 13 centers with more than 120 patients divided into four cohorts.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top